Clinical and immune effects of cetuximab and weekly low dose carboplatin and paclitaxel in head and neck cancer patients with poor performance status.

e18005Background: Patients with recurrent/ metastatic head and neck squamous cell carcinoma (HNSCC) with poor performance status (PS) have limited treatment options. Immune mechanisms are implicate...